Maitake beta-glucan (MBG) is an extract from the fruit body of the Grifola frondosa mushroom that is being widely used to treat cancer in Asia. We have previously reported that MBG enhances mouse bone marrow cell (BMC) hematopoiesis in vitro and protects BMC from doxorubicin (DOX) toxicity. In the current study, we investigated the ability of MBG to enhance hematopoiesis and to reduce the toxic effects of DOX on fresh human umbilical cord blood (CB) cells. MBG treatment significantly enhanced the colony formation unit (CFU) response of granulocytes-macrophages (CFU-GM response) over the whole dose range of 12.5 to 100 g/ml (P < 0.05). The addition of MBG to DOX-treated CB cells significantly protected granulocyte-macrophage colony formation from the toxicity of DOX, which otherwise produced strong hematopoietic repression. MBG also partially replaced recombinant human granulocyte colony-stimulating factor (rhG-CSF), as shown by a significant augmentation of the CFU-GM response in the absence of rhG-CSF. We found that MBG induces granulocyte colony-stimulating factor (G-CSF) production in CB CD33؉ monocytes, as detected by intracellular cytokine flow cytometric assessment. In contrast, we found that adult peripheral blood monocytes did not produce a significant G-CSF response to MBG, whereas both adult and CB monocytes produced G-CSF in response to lipopolysaccharide. These studies provide the first evidence that MBG induces hematopoietic stem cell proliferation and differentiation of CFU-GM in umbilical CB cells and acts directly to induce G-CSF.Maitake beta-glucan (MBG) is an extract from the fruit body of the Grifola frondosa mushroom that is widely used in Asia for the treatment of cancers, although the mechanism(s) of action is unclear (4). MBG contains glucan polysaccharide compounds that have a beta-1,6-glucopyranoside main chain with branches of beta-1,3-linked glucose (24). The results of experimental studies with animals suggest that MBG administered orally activates the host antitumor response through effects on the immune system rather than by direct cytostatic or cytotoxic effects on tumor cells (19,37). However, dose-response relationships have not been shown (15, 21). Since other beta-glucans have been found to reduce myelosuppression and to enhance hematopoiesis in vitro and the mobilization of stem cells in vivo in animal models (16, 27, 33), we initially tested the effects of MBG on mouse bone marrow cells. Those studies showed for the first time that MBG enhances murine bone marrow cell proliferation and differentiation into granulocytesmacrophages (GMs) in a dose-dependent manner (22). In the presence of the chemotherapy drug doxorubicin (DOX), MBG promoted bone marrow cell viability and protected the bone marrow stem cell colony formation unit response of GMs (CFU-GM response) from DOX-induced hematopoietic toxicity. On the basis of the results of our studies with the mouse, we are interested in the possible use of MBG for myelosuppression secondary to cancer chemotherapy and for ex vivo expa...